Funded Projects › FP7
PLOIDYNET · The impact of chromosomal instability on health: Molecular causes and consequences of aneuploidy
Aneuploidy, an abnormal number of chromosomes, is a hallmark of cancer cells, affecting the majority of all human tumours. Aneuploidy arises when errors occur during mitosis, as the duplicated chromosomes are distributed between the two new daughter cells. Paradoxically, aneuploidy appears to have detrimental consequences for the physiology of untransformed cells in vitro, inhibiting rather than stimulating proliferation. This suggests that cancer cells have acquired mutations that help them cope with aneuploidy. Although it is clear that aneuploidy can contribute to cancer, the molecular consequences of aneuploidy remain elusive, as does how aneuploidy contributes to malignant transformation. The scientific aim of this network is to determine and compare the molecular consequences of different levels of aneuploidy, both in vivo and in vitro. Our network will train 9 Early Stage Career and 2 Experienced researchers in the aneuploidy field. To this aim, we are combining the expertise of labs that study the causes of aneuploidy with labs that induce aneuploidy in model organisms and study its consequences and also with labs that focus on the development of therapeutics that selectively kill aneuploid cell progeny. Our network is comprised of 11 full participants in 4 member states and 1 associated country and one associated partner, and includes 3 commercial enterprises. Within this network, we will provide technical training through research projects, but also through workshops and dedicated courses organized by the participants of this network. A significant part of the training will be provided by the industrial partners. Participating investigators and trainees will meet at a yearly conference to exchange and discuss results. Trainees will thus become experts in the field of aneuploidy while rapidly building up a scientific network for themselves, putting them in an excellent position to become future leaders in this field.
Consortium · 14 organisations
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
NL · €329,920
CANCER RESEARCH UK LBG
UK · €53,009
THE UNIVERSITY OF MANCHESTER
UK · €296,057
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
NL · €154,078
EUROPEAN MOLECULAR BIOLOGY LABORATORY
DE · €67,186
UNIVERSITAT BASEL
CH · €272,516
MILTENYI BIOTEC GMBH
DE · €205,555
ACADEMISCH ZIEKENHUIS GRONINGEN
NL · €376,758
NETHERLANDS TRANSLATIONAL RESEARCHCENTER BV
NL · €219,979
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
DE · €181,639
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
NL · €91,033
THE FRANCIS CRICK INSTITUTE LIMITED
UK · €240,934
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
DE · €233,069
THE UNIVERSITY OF EDINBURGH
UK · €296,057
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.